Evidence map›Paper›PMID 25522432›Full record

ArticleThe international journal of neuropsychopharmacology2014

Manganese-enhanced magnetic resonance imaging reveals differential long-term neuroadaptation after methamphetamine and the substituted cathinone 4-methylmethcathinone (mephedrone).

Bjørnar den Hollander, Mateusz Dudek, Ilkka Ojanperä, Esko Kankuri, Petri Hyytiä, Esa R Korpi

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bjørnar den HollanderInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi). denhollander.bjornar@gmail.com.
Mateusz DudekInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi).
Ilkka OjanperäInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi).
Esko KankuriInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi).
Petri HyytiäInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi).
Esa R KorpiInstitute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland (Drs den Hollander, Dudek, Kankuri, Hyytiä, and Korpi); Hjelt Institute, Department of Forensic Medicine, Kytösuontie 11, FI-00014 University of Helsinki, Finland (Dr Ojanperä); Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Neurobiology and Ageing Programme, Life Sciences Institute, National University of Singapore, and SINAPSE, Singapore Institute for Neurotechnology, Singapore (Dr Korpi).
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years there has been a large increase in the use of substituted cathinones such as mephedrone (4-methylmethcathinone, 4-MMC), a psychostimulant drug that shows a strong resemblance to methamphetamine (METH). Unlike METH, which can produce clear long-term effects, the effects of 4-MMC have so far remained elusive. We employ manganese-enhanced magnetic resonance imaging (MEMRI), a highly sensitive method for detecting changes in neuronal activation, to investigate the effects of METH and 4-MMC on the brain.

methodsIn Wistar rats we performed a MEMRI scan two weeks after binge treatments (twice daily for 4 consecutive days) of METH (5 mg/kg) or 4-MMC (30 mg/kg). Furthermore, locomotor activity measurements and novel object recognition tests were performed.

resultsMETH produced a widespread pattern of decreased bilateral activity in several regions, including the nucleus accumbens, caudate putamen, globus pallidus, thalamus, and hippocampus, as well as several other cortical and subcortical areas. Conversely, 4-MMC produced increased bilateral activity, anatomically limited to the hypothalamus and hippocampus. Drug treatments did not affect the development of locomotor sensitization or novel object recognition performance.

conclusionsThe pattern of decreased brain activity seen after METH corresponds closely to regions known to be affected by this drug and confirms the validity of MEMRI for detecting neuroadaptation two weeks after amphetamine binge treatment. 4-MMC, unlike METH, produced increased activity in a limited number of different brain regions. This highlights an important difference in the long-term effects of these drugs on neural function and shows precisely the anatomical localization of 4-MMC-induced neuroadaptation.

Indexed as

Adaptation, PhysiologicalAnimalsBehavior, AnimalBody Temperature RegulationBrainBrain MappingBrain WavesCentral Nervous System StimulantsChloridesMagnetic Resonance ImagingManganese CompoundsMethamphetamineMotor ActivityNeuronal PlasticityPredictive Value of TestsRats, WistarCentral Nervous System StimulantsChloridesmanganese chlorideManganese CompoundsmephedroneMethamphetamine4-methylmethcathinonemagnetic resonance imagingmephedronemethamphetaminepsychostimulants

Identifiers

PMID25522432
PMCPMC4438547
OpenAlexW2139225621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.